RE: Views14 Apr 2021 10:04
We do not know as yet why ELI did not take up the option, but as a shareholder, I would rather Vlad turn down a poor offer from ELI, then simply give them HEMO on the cheap. We as shareholders would be up in arms if Vlad did this, so yes I am of the opinion that we continue as present, but put a longer time line on progress.
PS. Vlad stop tweeting and issue in stead clear and precise RNS's in the future.
Aspen
GLA